scholarly journals MASTER: a model to improve and standardize clinical breakpoints for antimicrobial susceptibility testing using forecast probabilities

2017 ◽  
Vol 72 (9) ◽  
pp. 2553-2561 ◽  
Author(s):  
Nicolas Blöchliger ◽  
Peter M. Keller ◽  
Erik C. Böttger ◽  
Michael Hombach
Keyword(s):  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
Clinical Breakpoints

scholarly journals Addressing the Antimicrobial Resistance of Ruminant Mycoplasmas Using a Clinical Surveillance Network

2021 ◽  
Vol 8 ◽  
Author(s):  
Maryne Jaÿ ◽  
François Poumarat ◽  
Adélie Colin ◽  
Agnès Tricot ◽  
Florence Tardy
Keyword(s):  
Antimicrobial Resistance ◽  
Antimicrobial Susceptibility ◽  
Swot Analysis ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
Published Data ◽  
Surveillance Strategy ◽  
Surveillance Network ◽  
Clinical Surveillance ◽  
Clinical Breakpoints

Antimicrobial resistance (AMR) surveillance of mycoplasmas of veterinary importance has been held back for years due to lack of harmonized methods for antimicrobial susceptibility testing (AST) and interpretative criteria, resulting in a crucial shortage of data. To address AMR in ruminant mycoplasmas, we mobilized a long-established clinical surveillance network called “Vigimyc.” Here we describe our surveillance strategy and detail the results obtained during a 2-year monitoring period. We also assess how far our system complies with current guidelines on AMR surveillance and how it could serve to build epidemiological cut-off values (ECOFFs), as a first attainable criterion to help harmonize monitoring efforts and move forward to clinical breakpoints. Clinical surveillance through Vigimyc enables continuous collection, identification and preservation of Mycoplasma spp. isolates along with metadata. The most frequent pathogens, i.e., M. bovis and species belonging to M. mycoides group, show stable clinicoepidemiological trends and were included for annual AST. In the absence of interpretative criteria for ruminant mycoplasmas, we compared yearly minimum inhibitory concentration (MIC) results against reference datasets. We also ran a SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis on the overall service provided by our AMR surveillance strategy. Results of the 2018–2019 surveillance campaign were consistent with the reference datasets, with M. bovis isolates showing high MIC values for all antimicrobial classes except fluoroquinolones, and species of the Mycoides group showing predominantly low MIC values. A few new AMR patterns were detected, such as M. bovis with lower spectinomycin MICs. Our reference dataset partially complied with European Committee on Antimicrobial Susceptibility Testing (EUCAST) requirements, and we were able to propose tentative epidemiological cut-off values (TECOFFs) for M. bovis with tilmicosin and spectinomycin and for M. mycoides group with tilmicosin and lincomycin. These TECOFFs were consistent with other published data and the clinical breakpoints of Pasteurellaceae, which are often used as surrogates for mycoplasmas. SWOT analysis highlighted the benefit of pairing clinical and antimicrobial resistance surveillance despite the AST method-related gaps that remain. The international community should now direct efforts toward AST method harmonization and clinical interpretation.

Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints

2020 ◽  
Author(s):  
Michael J Satlin ◽  
James S Lewis ◽  
Melvin P Weinstein ◽  
Jean Patel ◽  
Romney M Humphries ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Polymyxin B ◽  
Antimicrobial Susceptibility Testing ◽  
In Vitro Susceptibility ◽  
Susceptibility Data ◽  
European Committee ◽  
Clinical Breakpoints ◽  
State Concentration

Abstract Recent data on polymyxin pharmacokinetics, pharmacodynamics, toxicity, and clinical outcomes suggest these agents have limited clinical utility. Pharmacokinetics-pharmacodynamics data show a steady-state concentration of 2 μg/mL is required for killing bacteria with colistin minimum inhibitory concentrations of 2 μg/mL. Less than 50% of patients with normal renal function achieve this exposure, and it is associated with high risk of nephrotoxicity. This exposure does not achieve bacterial stasis in pneumonia models. Randomized and observational studies consistently demonstrate increased mortality for polymyxins compared with alternative agents. The Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) are 2 global organizations that establish interpretive criteria for in vitro susceptibility data. CLSI has recently taken the step to eliminate the “susceptible” interpretive category for the polymyxins, whereas EUCAST maintains this interpretive category. This viewpoint describes the opinions of these organizations and the data that were used to inform their perspectives.

Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of

2003 ◽  
Vol 1 (4) ◽  
pp. 273-278 ◽  
Author(s):  
Marco Romano ◽  
Riccardo Marmo ◽  
Antonio Cuomo ◽  
Teresa De Simone ◽  
Caterina Mucherino ◽  
...  
Keyword(s):  
Cost Saving ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing

NGHIÊN CỨU SỰ NHẠY CẢM VỚI KHÁNG SINH CỦA MỘT SỐ CHỦNG VI KHUẨN GÂY VIÊM ĐƯỜNG HÔ HẤP CẤP Ở TRẺ EM DƯỚI 6 TUỔI TẠI BỆNH VIỆN NHI THANH HÓA 2009 - 2014

2020 ◽  
Vol 4 (3) ◽  
Author(s):  
Hoai Do Ngoc
Keyword(s):  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
High Rate ◽  
Isolation Rate

From 43.574 fluid nasopharynx speciments of  the chidren inpatient under six we isolated total 21.769 types bacteria with isolation rate : 49.95%. In which the highest isolation rate for H. influenza, S. pneumoniae and M. catarrhalis were 13,94%; 7,11%; 1,43% respectively. Antimicrobial susceptibility testing shown all the types of  for H. influenza, S. pneumoniae and M. catarrhalis good susses to Fosphomycine, S. pneumoniae and M. catarrhalis good susses to Imipenem, H. influenza good susses to Azithromycine, S. pneumoniae good susses to Penicilline and Piperacilline, M. catarrhalis good susses to Tobramycine and Ofloxacine. All of  H. influenza, S. pneumoniae and M. catarrhalis were reported resistance to Tri/Sulpha, Chloramphenicol, Erythromycine in high rate.

Sign in / Sign up

Export Citation Format

Share Document